MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat.

Jasmine ChenAleks C GuanizoW Samantha N JakasekaraChaitanya InampudiQuinton LuongDaniel J GaramaMuhammad AlamgeerNishant ThakurMichael DeVeerVinod GanjuD Neil WatkinsJason E CainDaniel J Gough

Published in: Journal of experimental & clinical cancer research : CR (2023)

MYC is a potent driver of platinum resistance in SCLC that is effectively treated with fimepinostat.

Keyphrases

transcription factor
histone deacetylase
anti inflammatory
newly diagnosed